Figures & data
Table I. Results of the multiple Cox proportional hazards model for overall survival.
Figure 1. Overall survival after first dose of bevacizumab in patients with (solid lines) and without (dotted lines) bevacizumab-associated hypertension (p-value log rank test = 0.16). Bevacizumab associated hypertension was defined as 1) blood pressure of ≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic during the first 3 months after the start of bevacizumab in patients without prior hypertension, or 2) increase in systolic and/or diastolic blood pressure of > 10 mmHg during the first 3 months after the start of bevacizumab in patients with pre-existing hypertension. Censored patients (n = 4).
![Figure 1. Overall survival after first dose of bevacizumab in patients with (solid lines) and without (dotted lines) bevacizumab-associated hypertension (p-value log rank test = 0.16). Bevacizumab associated hypertension was defined as 1) blood pressure of ≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic during the first 3 months after the start of bevacizumab in patients without prior hypertension, or 2) increase in systolic and/or diastolic blood pressure of > 10 mmHg during the first 3 months after the start of bevacizumab in patients with pre-existing hypertension. Censored patients (n = 4).](/cms/asset/889b332d-c8d4-4241-a916-e85393ce0f16/ionc_a_852240_f0001_b.gif)